Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC003928 | Panoply™ Human CYFIP1 Knockdown Stable Cell Line | Inquiry |
| CSC-DC016839 | Panoply™ Human TTYH1 Knockdown Stable Cell Line | Inquiry |
| CSC-SC003928 | Panoply™ Human CYFIP1 Over-expressing Stable Cell Line | Inquiry |
| CSC-SC016839 | Panoply™ Human TTYH1 Over-expressing Stable Cell Line | Inquiry |
| CSC-RR00778 | YFP Reporter Cell Line - HGC-27 | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD04486Z | Human CYFIP1 adenoviral particles | Inquiry |
| AD17126Z | Human TTYH1 adenoviral particles | Inquiry |
| LV10165L | human CYFIP1 (NM_014608) lentivirus particles | Inquiry |
| LV10166L | human CYFIP1 (NM_001033028) lentivirus particles | Inquiry |
| LV28984L | human TTYH1 (NM_001005367) lentivirus particles | Inquiry |
| LV28985L | human TTYH1 (NM_020659) lentivirus particles | Inquiry |
| LV28986L | human TTYH1 (NM_001201461) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH272717 | shRNA set against Human CYFIP1 (NM_014608.2) | Inquiry |
| SHH272721 | shRNA set against Mouse CYFIP1 (NM_011370.3) | Inquiry |
| SHG215011 | shRNA set against Human CYFIP1(NM_001033028.1) | Inquiry |
| SHG215071 | shRNA set against Human CYFIP1(NM_014608.2) | Inquiry |
| SHH272725 | shRNA set against Rat CYFIP1 (NM_001107517.1) | Inquiry |
| SHH437536 | shRNA set against Human TTYH1 (NM_020659.3) | Inquiry |
| SHH437540 | shRNA set against Mouse TTYH1 (NM_021324.5) | Inquiry |
| SHH437544 | shRNA set against Rat TTYH1 (NM_001106225.1) | Inquiry |
| SHL105492 | shRNA set against Mouse Ttyh1(NM_021324.5) | Inquiry |
| SHL105660 | shRNA set against Mouse Ttyh1(NM_001001454.3) | Inquiry |
| SHL105718 | shRNA set against Mouse Ttyh1(NM_021324.5) | Inquiry |
| SHW017915 | shRNA set against Danio rerio CYFIP1 (NM_212759) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| OE-PNDC000413 | Human TTYH1 Nanodisc | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| MiUTR3H-07955 | TTYH1 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-12292 | TTYH1 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-12291 | TTYH1 miRNA 3'UTR clone | Inquiry |
| MiUTR1H-02599 | CYFIP1 miRNA 3'UTR clone | Inquiry |
| MiUTR1H-02598 | CYFIP1 miRNA 3'UTR clone | Inquiry |
| CDFR007206 | Rat Cyfip1 cDNA Clone(NM_001107517.1) | Inquiry |
| CDFR005982 | Rat Ttyh1 cDNA Clone(NM_001106225.1) | Inquiry |
| CDFH004629 | Human CYFIP1 cDNA Clone(NM_014608.2) | Inquiry |
| CDFH004628 | Human CYFIP1 cDNA Clone(NM_001033028.1) | Inquiry |
| MiUTR3H-07954 | TTYH1 miRNA 3'UTR clone | Inquiry |
| CDCS406818 | Human CYFIP1 ORF Clone (BC005097) | Inquiry |
| CDCS406240 | Human TTYH1 ORF Clone (BC019358) | Inquiry |
| CDCR374257 | Rat Cyfip1 ORF Clone(NM_001107517.1) | Inquiry |
| CDCR372993 | Rat Ttyh1 ORF Clone(NM_001106225.1) | Inquiry |
| CDCR297902 | Human CYFIP1 ORF Clone(NM_014608.2) | Inquiry |
| CDCR255113 | Mouse Ttyh1 ORF Clone(NM_021324.5) | Inquiry |
| CDCR250600 | Mouse Cyfip1 ORF Clone(NM_011370.3) | Inquiry |
| CDCR240748 | Mouse Cyfip1 ORF Clone(NM_001164661.1) | Inquiry |
| CDCR236333 | Mouse Ttyh1 ORF Clone(NM_001109765.1) | Inquiry |
| CDCR052432 | Mouse Cyfip1 ORF clone (NM_001164662.1) | Inquiry |
| CDCR052424 | Human CYFIP1 ORF clone (NM_001033028.1) | Inquiry |
| CDCR007662 | Mouse TTYH1 ORF clone(NM_001001454.3) | Inquiry |
| CDCH096612 | human TTYH1 ORF clone (NM_001201461.1) | Inquiry |
| CDCB195094 | Rabbit TTYH1 ORF clone (NM_001171395.1) | Inquiry |
| CDCB193741 | Rabbit CYFIP1 ORF clone (XM_002718278.2) | Inquiry |
| CDCR339685 | Human TTYH1 ORF Clone(NM_001005367.2) | Inquiry |
| CDCB179390 | Danio rerio CYFIP1 ORF Clone (NM_212759) | Inquiry |
Recent Research Progress
Cyfip1 [cytoplasmic FMRP-interacting protein 1 or specific Rac1-related protein 1 (SRA1)] is known to interact with FMRP (fragile X syndrome mental retardation protein), a mutation in fragile X syndrome (FXS) Protein, which has the function of inhibiting protein translation. Cfyip1 also contributes to the formation of the WAVE regulatory complex (WRC), which regulates actin polymerization in synapses. Recently, it has been shown that the functions of these two different protein complexes involving Cyfip1 converge to regulate spinal morphology and synaptic plasticity. These molecular studies have shown that the lack of Cfyip1 may lead to sudden triggering and dysfunction. Human genetic studies have identified Cfyip1 as a gene that is dysregulated in a variety of developmental brain diseases, including specific forms of Angelman and Prader-Willi syndrome, autism spectrum disorders, and schizophrenia.
Cyfip1 and autism and schizophrenia
Recently, studies have found that copy number variation in Cfyip1 is associated with autism, schizophrenia, and intellectual disability (Figure 1). Cfyip1 and the paralog CYFIP2 are enriched at the inhibitory postsynaptic site. Although up-regulation of Cfyip1 or CYFIP2 increases the frequency of excitatory synapses and miniature excitatory postsynaptic currents (mEPSCs), it has an opposite effect in inhibitory synapses, reducing their size and the amplitude of miniature inhibitory postsynaptic currents (mIPSCs). In contrast to the up-regulation of Cfyip1, it increases the expression of postsynaptic GABAA receptor b2/3-subunit and neuroligin 3 and enhances synaptic inhibition Cfyip1 after conditional knockout in major cortical major cells. Thus, Cfyip1 doses can affect both inhibitory synaptic structures and functions in both directions, and may result in excitatory/inhibitory (E/I) balance and changes in circuit dysfunction in Cfyip1-related neurological disorders.
Figure 1. Copy number variation (CNV) in CYFIP1 is associated with neuropsychiatric disorders. (Elizabeth C, et al. Cell Reports, 2019)
Cyfip1 and ALL
The mRNA and protein expression levels of Cyfip1 in ALL patients were significantly lower than those in normal peripheral blood lymphocytes (PBL). In addition, both mRNA and protein expression were negatively correlated with lymph node metastasis. In conclusion, detection of Cyfip1 mRNA and protein expression can provide clinically important information related to diagnosis, progression, and treatment modalities for ALL, and Cyfip1 may serve as a potential biomarker for diagnosis and prognosis in ALL.
Cyfip1 and SCC
Squamous cell carcinoma of the skin (SCC) represents one of the most common cancers in the general population and has a significant risk of metastasis. Cyfip1 expression has been reported to be down-regulated in SCC and inversely proportional to the histological differentiation of tumors. Cyfip1 mRNA is highly increased in human Notch1 overexpressing keratinocytes. Further manipulation of the Notch1 pathway in keratinocytes affected Cyfip1 levels, and chromatin immunoprecipitation assay confirmed that Notch1 binds directly to the Cyfip1 promoter. Cyfip1 may be a link between differentiation loss and invasive ability in malignant keratinocytes of cutaneous squamous cell carcinoma.
The results indicate that Cyfip1 is usually absent in epithelial colon, breast or lung cancer. A decrease in the expression of Cyfip1 was also observed during the invasion of these tumors and was associated with poor prognosis. Since Cyfip1 is commonly found in many diseases, its dysregulation seems to exacerbate symptoms, so the treatment of Cyfip1 function may be beneficial for many human diseases.
References: